PDCD1 and melanoma: TIGIT is often co-expressed with PD-1 and other immune checkpoints on CD8+TILs.Dual PD-1/TIGIT blockers have achieved higher clinical efficacy in melanoma compared with single immune checkpoint inhibition confirming the potential possibility of TIGIT as an immunotherapy target (16, 17).